MÖMustafa Öztürk

Mustafa Öztürk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mustafa Öztürk has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sequential Coronary Obstruction After Native TAVI: Immediate Acute Occlusion and Very Late Stent Compression by Aortic Wall Hematoma

    by Ali Rıza Akyüz, Murat Gökhan Yerlikaya, Mustafa Öztürk, Selim Kul

    Coronary obstruction is a rare but catastrophic complication of transcatheter aortic valve implantation (TAVI) associated with high mortality. While acute and delayed presentations have distinct pathophysiological mechanisms, their occurrence in the same patient is exceedingly rare. We present a unique case of a 91‐year‐old female who developed acute left main coronary artery (LMCA) obstruction immediately following native TAVI using a balloon‐expandable valve, which was successfully treated with bail‐out percutaneous coronary intervention (PCI). Three months later (> 60 days, classified as “Very Late” coronary obstruction), she presented with severe angina and heart failure. Intravascular ultrasound (IVUS) revealed extrinsic compression of the previously implanted coronary stent caused by a localized aortic wall hematoma. A repeat PCI with a stent‐in‐stent technique restored coronary flow, leading to complete clinical recovery. This case expands the known mechanical spectrum of very late coronary obstruction according to recent classification frameworks and highlights the vital role of intravascular imaging and multimodality assessment in diagnosis and management.

  • Open Access

    Electrocardiographic Evaluation of Patients with Crimean-Congo Hemorrhagic Fever

    by Emrah Aksakal, Sibel İba Yilmaz, Handan Alay, Oguzhan Ekrem Turan, Mustafa Öztürk, Gökhan Ceyhun, Omer Karasahi̇n

    Infectious diseases can affect the myocardium directly or through cytokines. Disruption of cardiac depolarization and repolarization is associated with the development of arrhythmia. In this study, we aimed to evaluate electrocardiographic (ECG) parameters in patients with Crimean-Congo Hemorrhagic Fever (CCHF). 42 patients hospitalized with the diagnosis of CCHF were included in the study. Heart rate, PR interval, P dispersion, QRS duration, QT interval and corrected QT, T peak T end, Tp-e/QT ratio, Tp-e/QTc ratio, and QT dispersion parameters were calculated from 12-lead ECGs at the time of admission and discharge. The mean age of the patients in the study was 45.8 ± 16.9 years. ECG parameters were found to be similar at admission and discharge (all p values>0.1). Major events such as life-threatening bleeding, significant hypotension, and shock were not observed in any of the patients. Platelet and white blood cell values were significantly increased at discharge compared to admission (78.3 vs 197.6 x103, p=0.01 and 2.8 vs 5.4 x103, p=0.006 respectively). In patients with CCHF, there was no significant change in ECG polarization parameters at the onset of the active infection process and during hospitalization period and these parameters found to be within normal limits.


  • Role of Systemic Immune-Inflammatory Index in Predicting the Development of In-Hospital Malignant Ventricular Arrhythmia in Patients With ST-Elevated Myocardial Infarction

    by Emrah Aksakal, Uğur Aksu, Oğuzhan Birdal, Mustafa Öztürk, Oktay Gülcü, Kamuran Kalkan, Ali F. Korkmaz, Cem Korucu, Merve Lazoğlu

    Many complications can be observed after ST-elevation myocardial infarction (STEMI). The systemic immune-inflammatory index (SII) is a sensitive indicator of the inflammatory state, and this parameter may also be associated with cardiovascular diseases. In this study, we investigated the relationship between malignant ventricular arrhythmias (MVA) development and SII in STEMI patients. A total of 1708 STEMI patients were included in the study. Propensity score matching (PSM) analysis was performed. Patients were divided into 2 groups according to the development of MVA, and predictors of MVA development were investigated. After the PSM analysis, the mean age of 158 patients was 61.6 years, and 68.4% were male. In the univariate analysis, neutrophil count, SII, C-reactive protein (CRP), albumin, and CRP/albumin ratio (CAR) were associated with the development of MVA; while in the regression analysis, CAR and SII was found to be independent predictors of the development of MVA. In this study, we demonstrated that SII is a better independent predictor than other inflammatory parameters for predicting the development of MVA. This index may be useful in clinical use.


  • Open Access

    B-type natriuretic peptide/ferritin ratio as a predictor of the risk of developing acute renal injury in acute decompensated heart failure

    by Gökhan Ceyhun, Mustafa Öztürk, Zafer Küçüksu, Sidar Şiyar Aydın, Mustafa Özkoç, Onur Altınkaya, Azman Ateş

    OBJECTIVES: Acute decompensated heart failure (ADHF) is a clinical condition that requires urgent diagnosis and treatment. Patients present with pulmonary capillary wedge pressure, pulmonary arterial pressure, and venous pressure elevation. Along with the progressive deterioration observed in the clinical picture, impairment or deterioration of kidney function may also occur. In this study, we evaluated the B-type natriuretic peptide (BNP)/ferritin ratio as a predictor of the risk of developing acute renal injury (ARI) in ADHF. METHODS: A total of 157 patients with a diagnosis of ischemic dilated cardiomyopathy for more than 6 months that presented to our clinic with ADHF were included in this cohort study. After the treatment protocol was applied, the sample was divided into two groups as patients with and without ARI. The BNP and ferritin levels were examined along with the routine blood parameters (BNP), and the BNP, ferritin, and BNP/ferritin values were compared between the groups. RESULTS: ARI was present in 34.3% (n = 54) of the patients, who were also found to have higher BNP (892.76 vs. 817.54), lower ferritin (86.78 ± 57.2 vs. 105.46 ± 38.3), and higher BNP/ferritin (10.48 ± 2.14 vs. 7.89 ± 1.89). The multivariate logistic regression analysis revealed the BNP/ferritin ratio as an independent risk factor for ARI (odds ratio = 3.19; 95% CI, 1.92-6.54; P = 0.001). Using the receiver operating characteristic curve, a cutoff value of 9.32 for BNP/ferritin ratio had a sensitivity of 81.8% and a specificity of 93.5% (area under the curve 0.842, P < 0.001) for the prediction of ARI. CONCLUSION: The BNP/ferritin ratio is a new parameter that can be used to draw attention to the severity of the treatment and renal function in ADHF cases in emergency situations.


  • Association between previous anticoagulant use and mortality among hospitalized patients with COVID-19

    by Oktay Gülcü, Emrah Aksakal, Selim Aydemir, Remziye Doğan, İbRahim Saraç, Sidar Şiyar Aydın, Mustafa Öztürk, Uğur Aksu, Kamuran Kalkan, İbrahim Halil Tanboğa

    Although COVID-19 disease primarily affects the respiratory system, it has been seen in many studies that it causes thromboembolic (TE) events in many tissues and organs. So that, to prevent TE can reduce mortality and morbidity. In this context, this study aimed to investigate the relationship between the previous use of warfarin or other new direct oral anticoagulants (OAC) and mortality in patients hospitalized with a diagnosis of COVID-19 before hospitalization. A total of 5575 patients who were diagnosed with COVID-19 were hospitalized and started treatment between March 21 and November 30, 2020 were included in the study. The primary outcome was in-hospital all-cause mortality. A retrospective cohort study design was planned. Patients were followed up until death or censoring on November 30, 2020. The candidate predictors for primary outcome should be clinically and biologically plausible, and their relationships with all-cause death should be demonstrated in previous studies. We considered all candidate predictors included in the model in accordance with these principles. The main candidate predictor was previous OAC use. The primary analysis method was to compare the time to deaths of patients using and not using previous OAC by a multivariable Cox proportional hazard model (CPHM). In the CPHM, previous OAC use was found to be associated with a significantly lower mortality risk (adjusted hazard ratio 0.62, 95% CI 0.42–0.92, p = 0.030). In hospitalized COVID-19 patients, in patients who previously used anticoagulantswas associated with lower risk of in-hospital death than in those who did not.


  • Open Access

    ST Segment Yükselmeli Miyokard İnfarktüsü Hastalarında Koroner Arter Hastalığının Ciddiyeti ile Serum Adropin Seviyesi Arasındaki İlişkinin Değerlendirilmesi

    by Mustafa Öztürk, Oguzhan Ekrem Turan, Engin Şebi̇n, Gökhan Ceyhun, Emrah Aksakal, Kamuran Kalkan, Oktay Gulcu, Ali Fuat Korkmaz, Murat Bayantemur

    En tr Objective: Adropin is associated with energy balance in tissues and organs. The SYNTAX score (SS) is used to determine the severity of ST-segment elevation myocardial infarction (STEMI). The aim of this study was to determine the relationship between serum adropin levels and disease severity in STEMI patients. Materials and Methods: Eighty-nine patients who underwent coronary angiography (CAG) for STEMI were included in the study. The STEMI patients were divided into two subgroups: Group 1(SS < 22) and Group 2 (SS ≥ 23). 43 patients who underwent CAG and had normal coronary arteries were included in the study as a control group. Results: Groups 1 and 2 included more male participants than the control group (89.7% and 74.2% vs. 34.9%, respectively, p < 0.001). The smoking rate was higher in Groups 1 and 2 than in the control group (55.1% and 34.4% vs. 11.6%, respectively, p≤0.001). Serum adropin levels were lower in Group 1 than in the control group (147.3 ± 149.2 mg/L and 228.1 ± 253.3 ng/L, p = 0.03). Serum adropin levels were the lowest in Group 2 (87.8 ± 23.2 ng/L, 147.3 ± 149.2 ng/L, and 228.1 ± 253.3 ng/L, p = 0.004). Serum adropin levels were also negatively correlated with SS (r = -0.33, p = 0.002). Conclusion: Serum adropin levels decreased more in STEMI patients than in those without coronary artery disease (CAD). In addition, serum adropin levels decreased with increasing SS;this indicates the severity of CAD. Amaç: Adropin doku ve organların enerji balansı ile ilişkilidir. SYNTAX skor (SS) ST segment yükselmeli miyokard infraktüsünün (STYMI) ciddiyetinin değerlendirilmesinde kullanılmaktadır. Bu çalışmada serum adropinseviyesiile STYMI hastalarının hastalık ciddiyeti arasındaki ilişkinin araştırılması amaçlandı. GereçveYöntemler: STYMI sebebiyle koroner anjiografi (KAG) yapılan 89 hasta çalışmaya dahil edildi. STYMI hastalar Grup 1 (SS < 22) ve Grup 2 (SS ≥ 23) alt gruplarına ayrıldı. KAG yapılan ve normal koroner arterler izlenen 43 hasta ise control grubu olarak çalışmaya dahil edildi. Bulgular: Grup 1 ve 2 de erkek cinsiyet control grubuna gore daha fazlaydı (sırasıyla % 89,7, 74,2 ve 34,9, p < 0.001). Sigara kullanım oranı Grup 1 ve 2 de kontrol grubuna gore daha fazlaydı (sırasıyla %55,1, 34,4ve 11,6, p≤0.001). Serum adropin seviyesi Grup 1 de kontrol grubuna göre anlamlı daha azdı (147,3 ± 149,2 mg/L ile 228,1 ± 253,3 ng/L, p = 0.03). Serum adropin seviyesi en düşük Grup 2 de saptandı (87,8 ± 23,2 ng/L, 147,3 ± 149,2 ng/L ve 228,1 ± 253,3 ng/L, p = 0.004). Serum adropin seviyesi SS ile negatif koroleydi (r = -0.33, p = 0.002). Sonuç: STYMI hastalarında serum adropin seviyeleri koroner arter hastalığı (KAH) olmayanlara göre düşüktür. SS yükseldikçe serum adropin seviyeleri azalmaktadır, bu da KAH ciddiyetini göstermektedir.

  • Evaluation of ventricular repolarization parameters during migraine attacks

    by Mustafa Öztürk, Oğuzhan Ekrem Turan, Kayıhan Karaman, Nuray Bilge, Gökhan Ceyhun, Ugur Aksu, Emrah Aksakal, Oktay Gulcu, Kamuran Kalkan, Selami Demirelli


  • Open Access

    A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction

    by Emrah Ipek, Mustafa Yolcu, Erkan Yildirim, Konca Altinkaynak, Saime Ozbek Sebin, Kamuran Kalkan, Oktay Gulcu, Emrah Ermis, Mustafa Ozturk

    (1) To investigate the role of azurocidin, an antimicrobial protein, in patients with ST segment elevation myocardial infarction (STEMI). (2) This single-center prospective observational study included patients with STEMI and healthy age- and sex-matched control subjects. Baseline demographic, clinical and biochemical data were compared between the two groups. Azurocidin levels at baseline were determined using an enzyme-linked immunosorbent assay. Multivariate linear regression analysis with enter method was used to test the association between azurocidin and independent variables, such as the thrombolysis in myocardial infarction (TIMI) score, synergy between percutaneous coronary intervention with TAXUS and cardiac surgery score, global registry of acute coronary events score, Killip class, C-reactive protein (CRP), and creatinine kinase-myocardial band (CK-MB). (3) A total of 76 patients with STEMI and 30 healthy control subjects were enrolled in the study. Mean ± SD azurocidin levels were significantly higher in patients compared with healthy controls (18.07 ± 13.99 versus 10.09 ± 5.29 ng/mL, respectively). In a receiver-operating characteristic curve analysis, an azurocidin cut-off level of >11.46 ng/mL had 74% sensitivity and 58% specificity in predicting myocardial infarction. Azurocidin levels had a positive correlation with TIMI score (r = 0.651). In multivariate linear regression analysis, the TIMI score was an independent predictor of the azurocidin level. (4) Azurocidin is an infection marker that may be important in patients with STEMI.